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Abstract
Background: We evaluated plasma ASP and its precursor C3 in type 2 diabetic men with/without
rosiglitazone (ROSI) treatment compared to healthy non-obese men. We tested (1) whether
plasma ASP or C3 are altered postprandially in subcutaneous adipose tissue or forearm muscle
effluent assessed by arteriovenous (A-V) differences in healthy lean men and older obese diabetic
men and (2) whether treatment with ROSI changes the arteriovenous gradient of ASP and/or C3.
Methods: In this ongoing placebo-controlled, crossover, double-blinded study, AV differences
following a mixed meal were measured in diabetic men (n = 6) as compared to healthy men (n = 9).
Results:  Postprandial arterial and adipose venous TG and venous NEFA were increased in
diabetics vs. controls (p < 0.05–0.0001). ROSI treatment decreased postprandial arterial TG (p <
0.001), adipose venous NEFA (p < 0.005), reduced postprandial glucose (p < 0.0001) and insulin
concentrations (p < 0.006). In healthy men, there was no change in postprandial C3, but an increase
in adipose venous ASP vs. arterial ASP (p < 0.02), suggesting ASP production, with no change in
forearm muscle. In older, obese diabetic subjects, arterial C3 was greater than in controls (p <
0.001). Arterial C3 was greater than venous C3 (p < 0.05), an effect that was lost with ROSI
treatment. In diabetics, postprandial venous ASP was greater than arterial (p < 0.05), indicating ASP
production, an effect that was lost with ROSI treatment (p < 0.01).
Conclusion:  Increased postprandial venous production of ASP is specific for adipose tissue
(absent in forearm muscle). Increased postprandial C3 and ASP in diabetic subjects is consistent
with an ASP resistant state, this state is partially normalized by treatment with ROSI.
Background
Nowadays, adipose tissue is recognized as an important
endocrine organ in humans. Not only is its function of
storing unlimited energy as fat a widely recognized fact, its
secretory role is subject to intense research in recent years,
particularly with the increasing incidence of obesity and
cardiovascular disease related to lipid homeostasis distur-
bance [1-4]. Recent research has disclosed a group of adi-
pokines which include leptin, acylation stimulating
protein (ASP), adiponectin, tumor necrosis factor α, IL-6
and resistin, among others. Many of these factors have
been shown to play a central role in adipocyte metabo-
lism from communication with a variety of tissues to
allowing the adipocyte to sense its own energy stores, to
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influencing energy expenditure as well as its own mass [1-
4].
In the adipocytes, through the interaction of factor B,
adipsin and complement component C3 (precursor to
ASP), all three proteins being secreted by adipocytes in a
differentiation-dependent manner [5,6], a 76 amino acid
protein of 8.9 KDa is formed: C3a-des-Arg, also identified
as Acylation Stimulating Protein, (ASP) [7]. At the level of
the adipose tissue, ASP acts in an autocrine fashion, stim-
ulating free fatty acid esterification to form triglycerides
(TG), by stimulating diacylglycerol acyltransferase [8,9],
the enzyme that regulates the last step in TG synthesis;
thus stimulating TG storage in adipocytes. In addition,
ASP stimulates glucose uptake through the translocation
of glucose transporters Glut 1 and Glut 4 from the intrac-
ellular pool to the cell membrane. Finally, similar to insu-
lin, ASP inhibits hormone sensitive lipase via stimulation
of phosphodiesterase, thus inhibiting lipolysis in human
adipocytes [5,7,10] reviews [11,12]. ASP interacts with
C5L2, a G protein coupled receptor, to initiate a signalling
cascade that stimulates both fatty acid esterification and
glucose transport [9,13]. While no direct role for C3 in
lipid metabolism has been proposed, ASP appears to be
an important determinant of postprandial lipemia in
both human [14] and mouse models [15-19]. In addition,
previous physiological studies showed that ASP adminis-
tration decreases plasma NEFA levels and enhances post-
prandial TG clearance in both wildtype [15] and obese
[20] mice. In complement C3(-/-) ASP deficient mice, the
lack of ASP results in delayed postprandial TG clearance,
which is normalized acutely through ASP injection. The
mice are characterized by reduced adipose tissue with a
compensatory up-regulation of energy expenditure [17-
19,21,22].
In humans, fasting ASP correlates with the magnitude of
postprandial TG clearance independently of fasting TG
[14]. Men demonstrated greater delays in TG clearance
than women, reflected by increased fasting ASP. We have
previously demonstrated, using venoarterial gradients
across a subcutaneous adipose tissue bed, that there is a
postprandial increase in adipocyte production of ASP in
healthy subjects [23]. Further, study in non-obese and
obese women, demonstrated that TG clearance, NEFA
uptake into adipose tissue, as well as early postprandial
venoarterial ASP production were all significantly greater
in obese women [24]. Interestingly, in vitro studies indi-
cate that chylomicrons and insulin increase both ASP and
C3 production in human adipocytes [25-27].
Both ASP and its precursor C3 have been suggested to be
altered in disease states including diabetes and cardiovas-
cular disease, but a detailed comparison between the two
proteins has not been determined (review [28]). ASP and
C3 are both increased in obesity [28], even in very young
children [29]. ASP and C3 levels also increase in diabetics
[28], even in the absence of changes in body weight [30].
First degree relatives of type 2 diabetics have increased C3
[31] and in a population-based cohort study, C3 was asso-
ciated with increased risk for diabetes development [32].
The aims of this study were to evaluate plasma ASP and its
precursor C3 in type 2 diabetic men with and without
treatment with rosiglitazone (ROSI) compared to healthy
non-obese men. We tested (1) whether plasma ASP or C3
concentrations are altered postprandially in adipose tissue
or muscle bed effluent as assessed by arterio-venous dif-
ferences in healthy lean men and diabetic men and (2)
whether treatment with ROSI changes the arterio-venous
gradient of ASP and/or C3.
Materials and methods
Subjects
Nine non-obese healthy men and six diabetic men (before
and after treatment with ROSI) were studied. The present
diabetic subjects are a subset of a larger double-blind, pla-
cebo-controlled, cross-over study [33]. Inclusion criteria
of diabetic subjects included the following: age 30–70
years, fasting plasma glucose 7–12 mmol/L and a BMI
greater than 24 kg/m2. Subjects were excluded if treated
previously with oral hypoglycaemic agents or any medica-
tion known to affect glucose metabolism. No subjects had
cardiac, liver, renal, or chronic disease or microvascular
complications. Subjects were administered ROSI 4 mg
twice daily for 12 weeks followed by placebo for 12 weeks,
or vice versa (split equally between the subjects). At the
end of each period, patients were evaluated following a
10-h overnight fast, with no alcohol or vigorous exercise
in the preceding 24-h. The study was approved by the clin-
ical research ethics committee at all authors' institutions
and all subjects gave their written informed consent.
Experimental design of tissue specific arteriovenous 
analysis
Venoarterial (V-A) studies were conducted in a tempera-
ture-controlled room (23°C) as described in detail previ-
ously [33]. Briefly, a cannula was inserted retrogradely
into a hand vein and the hand was warmed in a box at
60°–70°C so that arterialized blood samples could be
obtained. A 10-cm 22-gauge catheter was then introduced
over a guide wire into one of the superficial veins on the
anterior abdominal wall and threaded toward the groin,
so that its tip lay just superior to the inguinal ligament.
Samples from this cannula represent the venous effluent
from the subcutaneous abdominal adipose tissue, uncon-
taminated by muscle drainage and with only a minor con-
tribution from skin. Venous blood from muscle was taken
retrogradely from a vein draining the deep structures of
the forearm. All catheters were kept patent with saline andNutrition & Metabolism 2007, 4:11 http://www.nutritionandmetabolism.com/content/4/1/11
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heparin was not administered. The subjects rested for at
least 30 min after insertion of the catheters and before any
samples were taken. Subjects consumed a mixed meal
containing 40 g olive oil, 400 mg emulsifier, 200 mL
skimmed milk and Rice Krispies (Kellogg Company, Man-
chester, UK) containing 40 g fat and 40 g carbohydrate.
Blood samples were taken at each time point simultane-
ously from all three sites for 6-h after the meal. The sam-
ples were centrifuged and plasma was stored at -70°C.
Analyses
Plasma TG, glucose, NEFA and insulin concentrations
were measured as described previously [34]. Human ASP
was assayed as previously described [23,35]. The intra-
assay variability was 4% whereas the inter-assay variability
was 8%. Complement C3 was measured as described pre-
viously [26]. For the control group, only samples from n
= 5 subjects were available for analysis. Arteriovenous
(AV) differences were calculated as [venous-arterial] val-
ues. Fatty acid transcapillary flux, the net movement of
fatty acid across the endothelium in the adipose tissue,
was measured as: [3 × TG AV flux] + [NEFA AV flux].
Statistics
All results are presented as means ± standard error of the
mean (sem). Statistical differences for the data were calcu-
lated by 2-way repeated measures analysis of variance
(RM-ANOVA). The total area under the curve (AUC) for
C3 and ASP were calculated by a trapezoidal technique,
with no basal subtraction. For transcapillary flux, the
incremental AUC was calculated by trapezoidal technique
using the fasting (t = 0) as baseline value. The groups were
compared with an unpaired t-test or one-way ANOVA
(followed by Bonferroni post hoc test) unless the data
were not normally distributed, in which case a Mann-
Whitney test was applied. A p value of NS indicates not
significant.
Results
Baseline values of study subjects
Male patients with type 2 diabetes were examined before
and after treatment for 12 weeks with ROSI and compared
with control subjects as shown in Table 1. Subjects with
type 2 diabetes were older and more obese with signifi-
cantly higher circulating levels of glucose compared to
control subjects. With ROSI treatment, there was a signif-
icant decrease in glucose, as expected, although values still
remained higher than in control subjects. Neither fasting
TG nor NEFA changed significantly.
Fasting and postprandial insulin and glucose levels in 
diabetics plus ROSI treatment
As shown in figure 1 for all three groups, circulating insu-
lin increased after a mixed meal. However, type 2 diabetic
subjects had greater circulating insulin levels as compared
to control subjects (p < 0.03 RM-ANOVA). These levels
were significantly decreased with ROSI treatment (p =
0.006 RM-ANOVA) such that they were no longer signifi-
cantly increased compared to control subjects (p NS).
Glucose levels in the general circulation (arterial) and
from subcutaneous abdominal adipose tissue drainage
(venous) for the three groups of subjects are shown in Fig-
ure 1B and 1C, respectively. For both arterial and venous
blood samples, glucose increased significantly postpran-
dially, and was significantly higher in type 2 diabetic sub-
jects as compared to control subjects (p < 0.0001 and p <
0.0001 respectively, by RM-ANOVA). While ROSI treat-
ment significantly decreased circulating glucose (p <
0.0001 and p < 0.0001 for arterial and venous, respec-
tively, by RM-ANOVA), glucose levels still remained sig-
nificantly above controls (p < 0.0001 and p < 0.0001 for
arterial and venous, respectively, by RM-ANOVA).
ROSI effects on plasma TG and non-esterified fatty acids 
(NEFA)
As shown in figure 2, there were significant differences in
fasting and postprandial TG and NEFA between the
groups. Type 2 diabetics had markedly higher fasting and
postprandial TG levels as compared to controls for both
arterial (Figure 2A) and venous (Figure 2B) TG, p < 0.0001
and p < 0.005, respectively, by RM-ANOVA. While ROSI
significantly reduced postprandial arterial TG in type 2
diabetics (p < 0.001, by RM-ANOVA), there was no signif-
icant change in venous TG levels (p NS, by RM-ANOVA),
and in both cases, TG remained substantially greater than
the control subjects (p < 0.05 and p < 0.005 for arterial
and venous respectively, vs. controls, by RM-ANOVA).
Arterial and venous NEFA levels are shown in figure 2C
and 2D. There was no difference in arterial NEFA levels
(2C) between all three groups, although in each case there
was a postprandial decrease between 1 and 3 hours. With
respect to venous output, for all three study groups there
was a positive (and significant) NEFA production across
the adipose tissue bed (venous vs. arterial, p < 0.0001).
However, there were differences in venous NEFA output
between the three groups. The control group demon-
strated a striking NEFA suppression while the diabetic
group displayed minimal NEFA suppression of venous
output, p < 0.05 diabetics vs. controls. ROSI treatment led
to a normalization of the NEFA suppression (p < 0.005
diabetics vs. ROSI, and p NS for ROSI vs. control) that
appeared to be maintained even longer than in the control
group (up to 4–5 hours).
Adipose tissue and skeletal muscle venoarterial ASP and 
C3 changes in healthy non-obese men
We first examined postprandial changes in ASP and C3
(precursor to ASP) in normal healthy men (Figure 3). For
C3, samples were available only for n = 5 men. There wasNutrition & Metabolism 2007, 4:11 http://www.nutritionandmetabolism.com/content/4/1/11
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no postprandial change in C3 levels in control subjects for
either arterial or adipose tissue venous output (Figure 3A).
Similarly, there was no change in muscle bed output (Fig-
ure 3A), nor was there any significant difference between
the three tissue sources. By contrast, as shown in Figure
3B, while general circulating arterial ASP concentrations
remained constant postprandially, there was a marked
increase in venous adipose tissue effluent postprandially,
demonstrating a positive adipose tissue ASP production
in men (p < 0.02). However, there was no change in ASP
concentrations from the muscle venous effluent, as com-
pared to general circulating levels.
ROSI decreases complement C3 and ASP production
Results for complement C3 in older, obese diabetic sub-
jects pre and post treatment are shown in Figure 4. By con-
trast to control subjects, fasting arterial C3 was higher in
diabetic subjects (2.6 ± 0.74 vs. 0.76 ± 0.06, p < 0.05). As
shown in Figure 4A, postprandial arterial C3 was signifi-
cantly increased relative to venous (p < 0.05). With ROSI
treatment, fasting arterial C3 was decreased (1.33 ± 0.17,
p NS vs. control) and there was no longer any difference
between arterial and venous concentrations (p NS, Figure
4B), similar to results in control subjects. As with the con-
trol subjects, muscle output was not statistically different
from arterial levels for both diabetics pre and post ROSI
treatment (data not shown). A direct comparison of C3
total area-under-the-curve (AUC) for all groups is shown
in Figure 4C. Postprandial circulating (arterial) and adi-
pose drainage (venous) C3 in diabetics pre and post treat-
ment are all significantly greater than control C3 (p <
0.001), despite significant decreases in arterial C3 AUC in
diabetics with ROSI treatment (p < 0.05).
Results for ASP in older, obese diabetic subjects are shown
in Figure 5. Fasting arterial ASP tended to be increased
(but not significantly) in diabetic subjects (64.0 ± 10.4
diabetics vs. 38.6 ± 11.2 nM controls). Nonetheless, post-
prandially, there is a significant arteriovenous difference
in ASP over the 6 hour period (Figure 5A, p < 0.05 by 2
way ANOVA). While there is no change in fasting circulat-
ing arterial ASP levels with ROSI treatment (62.5 ± 10.8
nM), there is no longer any significant adipose tissue gen-
eration of ASP (Figure 5B, pNS). As shown in Figure 5C,
ASP total AUC in both arterial and venous pools in diabet-
ics is significantly increased compared to control subjects
(p < 0.001 and p < 0.01 respectively). With ROSI treat-
ment, arterial ASP AUC remained significantly increased
relative to control (p < 0.01), the adipose venous effluent
was significantly decreased compared to pre-treatment (p
< 0.01) and is no longer significantly increased relative to
control venous ASP AUC (pNS).
Fatty acid transcapillary flux
Fatty acid transcapillary flux, which measures the net
movement of fatty acids across the endothelium into adi-
pose tissue, is shown in Figure 6 for all three groups of
subjects. As shown in Figure 6A, for the controls, the flux
is significantly negative at fasting (taken as baseline
value), as a consequence of active intracellular adipose TG
lipolysis releasing fatty acids. Conversely, during the post-
prandial period, the flux is significantly positive, repre-
senting a net flux of fatty acids into the adipose tissue for
storage, with a robust shift from negative-to-positive-to-
negative evident in the control subjects (incremental AUC
8013 ± 1828). In the diabetic subjects, both the fasting
and postprandial responses are significantly blunted, with
little oscillation from negative to positive (incremental
AUC 2526 ± 748, ANOVA p = 0.03, p < 0.05 diabetics vs.
control). With ROSI treatment (Figure 6B), there is some
improvement in the negative to positive shift such that
there is now no difference with the control group (incre-
mental AUC 3233 ± 932, pNS vs. control).
Discussion
In the postprandial period, a series of interrelated events
are occurring in the adipose tissue. One of the principal
functions of the adipose tissue is to store energy. This
function is attained in healthy people through the interac-
tion of a number of hormones acting on the tissue. We
have previously demonstrated in non-obese and obese
women that ASP is produced postprandially across an adi-
pose tissue bed [23,24]. The present study is the first to
demonstrate this in an all-male study with lean healthy
men and in older, obese diabetic men, and further to
demonstrate that this is particular to adipose tissue, as the
Table 1: Fasting Plasma Lipid and Hormone Levels
Fasting Values Control n = 9 Diabetics n = 6 Diabetics + ROSI n = 6 ANOVA
Age (years) 36.4 ± 2.9 54.3 ± 4.2** 54.3 ± 4.1** 0.002
BMI (kg/m2) 24.3 ± 3.0 32.2 ± 2.1** 33.2 ± 2.0** 0.007
Glucose (mmol/L) 5.3 ± 0.15 8.84 ± 0.80* 7.0 ± 0.59 0.003
Triglyceride (umol/L) 1098 ± 177 2148 ± 399** 2152 ± 535 NS
NEFA (umol/L) 513 ± 41 650 ± 99 568 ± 61 NS
Insulin (pmol/L) 70.5 ± 5.1 121.0 ± 28.6 86.7 ± 11.7 NS
Fasting plasma glucose, triglyceride, NEFA and insulin levels are presented as mean ± SEM where * p < 0.05 and ** p < 0.01 compared to control 
analyzed by ANOVA with Bonferroni post hoc test, where NS = not significant.Nutrition & Metabolism 2007, 4:11 http://www.nutritionandmetabolism.com/content/4/1/11
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ASP gradient over a muscle bed is neither positive nor neg-
ative.
Adipose tissue function is particularly disturbed in
patients with type 2 diabetes, demonstrated by alterations
in many adipose tissue hormones (leptin, adiponectin,
ASP) both independently of, and related to, the accompa-
nying obesity (reviews [3,36,28]). The specific focus of
this study was to examine the association between post-
prandial NEFA and TG metabolism and ASP production
in patients with type 2 diabetes compared to controls, and
further to evaluate the effects of ROSI treatment. The
present study demonstrated that basal C3 and ASP are
increased in type II diabetics; and in spite of increased
basal levels, there is further postprandial production of
ASP across an adipose tissue bed. With ROSI treatment,
fasting C3 decreased, yet there was little change in fasting
ASP with the most striking change being a loss of post-
prandial ASP production.
Why are fasting and postprandial C3 and ASP increased in
type 2 diabetics? Previous studies have demonstrated
increased C3 and ASP in diabetic subjects (review [28]).
However, to our knowledge, this is the first study examin-
ing postprandial ASP and C3 adipose tissue fluxes in dia-
betic subjects. Firstly, the increased BMI in these diabetic
subjects partially explains the high baseline levels of ASP
and C3, as obesity (without diabetes) is associated with
increased ASP and C3 (review [28]). However, even in
non-obese subjects, both ASP and C3 correlate with
parameters of glucose and insulin homeostasis (review
[28]). Even in the absence of obesity, lean diabetics have
increased plasma ASP and C3 [30]. As ASP has similar
effects to insulin for fat storage (stimulates TG synthesis,
increases glucose uptake, inhibits lipolysis) and these
patients are insulin resistant, there may initially be
increased secretion of ASP to compensate for adipose
insulin resistance. Further, as ASP has been shown to
enhance insulin secretion in cellular and rodent models,
ASP may also enhance insulin secretion in humans [37].
On the other hand, it has been shown that, in healthy
men and women, fasting plasma ASP directly correlates
with postprandial TG clearance [14]; delayed TG clearance
is associated with higher fasting ASP, suggesting the pres-
ence of an ASP resistant state. In diabetics, as the insulin
resistant state progresses, ASP resistance may be present as
well.
Why do fasting C3 and postprandial ASP production
decrease with ROSI treatment? The putative function of
ASP in adipose tissue is to promote storage of TG. There
was a substantial lowering of ASP output from adipose tis-
sue in response to ROSI, something that was clearly disso-
ciated with minimal change in the transcapillary flux of
fatty acids. There are multiple potential mechanisms to
explain these changes. In principal, ASP could either play
a minor role in this process, due to ASP resistance, or the
action of ASP has been drastically changed by ROSI. Treat-
ment with ROSI results in major changes in glucose
homeostasis and increased insulin action (review [38]),
Fasting and postprandial insulin and glucose levels in diabetics  plus ROSI treatment Figure 1
Fasting and postprandial insulin and glucose levels in diabetics 
plus ROSI treatment: Following a standardized mixed meal, 
arterial insulin (A), arterial glucose (B) and adipose tissue 
venous glucose (C) were measured serially from 0 to 6 hours 
in control (n = 9), diabetics (n = 6) and diabetics treated with 
rosiglitazone (ROSI). Results are expressed as average ± sem 
with detailed statistics presented in the text, all comparisons 
used RM-ANOVA.
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thereby reducing the necessity of increased ASP. ROSI-
mediated enhanced insulin action on adipose tissue may
decrease postprandial ASP production, possibly because
less ASP is required to exert the same function. At the level
of adipose tissue, (i) decreased NEFA release due to effec-
tive postprandial suppression of hormone sensitive lipase
action, (ii) increased lipoprotein lipase to enhance post-
prandial TG clearance, and (iii) increased intracellular
capacity to channel NEFA for TG synthesis would all
decrease the demands of ASP action/compensation. The
changes in fatty acid transcapillary flux are an indirect
reflection of all these processes, and the shift towards a
more normal flux with ROSI treatment may indicate not
only an improvement in insulin action on adipose tissue,
but also an improvement on ASP action on adipose tissue.
ROSI has been shown recently to have effects on all these
processes, including increases in adipose tissue expression
of FAT/CD36 and FABP4 (both important in NEFA chan-
nelling) and lipoprotein lipase [33]. Lastly, ASP and C3
may decrease because of up-regulation of the ASP receptor
C5L2, increasing ASP sensitivity. We propose that, in a sit-
uation comparable to increased circulating insulin reflect-
ing insulin resistance that increased plasma ASP is
indicative of ASP resistance. By analogy, decreased post-
prandial ASP production suggests greater ASP sensitivity,
with less ASP needed for the same action. In support of
this, we have recently demonstrated that ROSI increases
C5L2 expression and ASP functional response in adi-
pocytes [39].
What is the mechanism both for the increased production
of ASP in diabetic subjects and for the decreased ASP gen-
eration with ROSI production? ASP is produced through
the cleavage of C3, via interaction with factor B and
adipsin (all produced in adipocytes). In vitro in human
adipocytes, both insulin and chylomicrons increase ASP
through direct effects on increased C3 expression and
secretion, and this may be one mechanism for the
ROSI effects on plasma TG and non-esterified fatty acids (NEFA) Figure 2
ROSI effects on plasma TG and non-esterified fatty acids (NEFA): Following a standardized mixed meal, arterial TG (A), adi-
pose venous TG (B), arterial NEFA (C) and adipose venous NEFA (D) were measured serially from 0 to 6 hours in control (n 
= 9), diabetics (n = 6) and diabetics treated with rosiglitazone (ROSI). Results are expressed as average ± sem with detailed 
statistics presented in the text, all comparisons used RM-ANOVA.
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increased ASP (increased substrate availability) and C3 in
diabetic subjects [26]. However, with ROSI treatment,
changes in circulating postprandial C3 were relatively
small, but postprandial generation of ASP was completely
blocked. This is even more striking considering that only
a small percentage of C3 is converted to ASP. Conversion
of C3 to ASP is tightly regulated: in plasma, all three com-
ponents required are freely circulating, yet little ASP is
present. In vitro, mixing the three proteins together does
not result in ASP generation, unless artificially activated
[10]. It has been suggested that a specific cell surface com-
ponent is required for conformational activation,
although the nature of that site is unknown. In vivo in the
present study, the adipose tissue bed is competent for ASP
generation, but a trans-muscle gradient was negative.
Therefore we hypothesize the existence of a controlled
mechanism which initiates ASP generation, which is
influenced by ROSI treatment.
ROSI decreases complement C3 in diabetic subjects Figure 4
ROSI decreases complement C3 in diabetic subjects: Follow-
ing a standardized mixed meal, arterial and adipose venous 
complement C3 were measured serially from 0 to 6 hours in 
diabetics (A: n = 6) and diabetics treated with rosiglitazone 
(B: n = 6 ROSI). Results are expressed as average ± sem 
where the statistical comparison of venous vs. arterial for 
each group is provided within the graph (using RM-ANOVA). 
Detailed statistics comparing groups are presented in the 
text. In Panel C, results are given for calculated total area-
under-the-curve (AUC) for C3 in control, diabetics and dia-
betics treated with ROSI, where *** p < 0.001 vs. the 
matched arterial or adipose venous control.
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detailed statistics presented in the text, all comparisons used 
RM-ANOVA.
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Conclusion
In summary, ASP production appears to be specific to the
adipose tissue milieu, and is increased in diabetic subjects
both fasting and postprandially. ROSI treatment, in addi-
tion to the many other demonstrated actions of this
potent class of drugs, also decreases ASP production in
adipose tissue.
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